Novel pain killers without adverse effects are urgently needed. Opioids induce central and intestinal side effects such as respiratory depression, sedation, addiction, and constipation. We have recently shown that a newly designed agonist with a reduced acid dissociation constant (pK a ) abolished pain by selectively activating peripheral μ-opioid receptors (MOR) in inflamed (acidic) tissues without eliciting side effects. Here, we extended this concept in that pK a reduction to 7.22 was achieved by placing a fluorine atom at the ethylidene bridge in the parental molecule fentanyl. The new compound (FF3) showed pH-sensitive MOR affinity, [ 35 S]-GTPγS binding, and G protein dissociation by fluorescence resonance energy transfer. It produced injury-restricted analgesia in rat models of inflammatory, postoperative, abdominal, and neuropathic pain. At high dosages, FF3 induced sedation, motor disturbance, reward, constipation, and respiratory depression. These results support our hypothesis that a ligand's pK a should be close to the pH of injured tissue to obtain analgesia without side effects. Published: xx xx xxxx OPEN www.nature.com/scientificreports/
Opioid receptor agonists are the most powerful drugs to treat severe acute and cancer-related pain. However, major problems have emerged due to their epidemic misuse and adverse effects 1 . These side effects comprise sedation, respiratory depression, addiction, nausea, and constipation, and are mediated by central or intestinal opioid receptors 2, 3 . The analgesic effects result from the activation of both central and peripheral opioid receptors via inhibitory G-proteins, which dissociate into G αi and G βγ subunits. Further downstream signaling leads to suppression of adenylyl cyclases and the modulation of ion channels, resulting in an overall decrease in neuronal excitability 2 . Many experimental and clinical studies revealed that a substantial proportion of opioid analgesia is mediated by the activation of opioid receptors on peripheral sensory neurons (reviewed in 3, 4 ). Numerous pain syndromes (e.g. arthritis, neuropathy, postoperative pain, cancer) are accompanied by injury-induced tissue acidosis and upregulation of such peripheral opioid receptors 3, [5] [6] [7] . Therefore, the potential of peripheral opioid receptors as drug targets is increasingly recognized 8, 9 . In contrast to previous pharmacokinetic concepts (reviewed in 3 ) , we recently developed a new pharmacodynamics-based design for peripherally-acting opioids lacking central or intestinal side effects 5 . This strategy is based on computational simulations of pathological receptor conformations and the finding that the protonation state of a ligand is crucial for its activity at opioid receptors. We hypothesized that the ligand's pK a should be reduced to values close to the acidic pH of injured tissue. This was achieved by fluorination of the piperidine ring in the μ-opioid receptor (MOR) agonist fentanyl, leading to the compound (±)-N-(3-fluoro-1-phenethylpiperidine-4-yl)-N-phenyl propionamide (NFEPP). In addition, our original computer simulations suggested hydrogen/fluorine exchange in fentanyl′s ethylidene SCIenTIFIC REPORTS | (2018) 8:8965 | DOI:10.1038/s41598-018-27313-4 bridge 5 . Accordingly, the compound (±)-N-[1-(2-fluoro-2-phenylethyl)piperidine-4-yl]-N-phenyl propionamide (FF3) was synthesized by a contractor (ASCA GmbH Berlin) and tested in vitro and in vivo in the present study.
Results
Computational design of FF3. Our previous in silico studies demonstrated that exchanging hydrogen by fluorine at distinct positions in the fentanyl molecule decreases its pK a value 5 . An electron withdrawing moiety within a distance of two carbon bonds ( Fig. 1A , green circles) of the acidic nitrogen atom (Fig. 1A , blue circle) is able to decrease the pK a such that the new molecule (FF3) is protonated in acidic and deprotonated in healthy tissue 5 . By choosing the fluorine atom, one hydrogen is replaced by only one other atom. Therefore, the overall size, geometry, and MOR binding properties of FF3 should not change significantly. To estimate its pK a , we used the B3LYP functional with a 6-31 + G* basis. In contrast to single starting structures used previously 5 , ensembles of structures derived from molecular dynamics simulations were now the basis for the calculations yielding an averaged pK a value of 6.01. Experimental measurements by a contractor resulted in a pK a of 7.22 (Table 1 ).
FF3 preferentially binds to and activates MOR at low pH. In membrane preparations of MOR-transfected Human Embryonic Kidney-293 (HEK293) cells, FF3 showed increased potency to displace the radioactively-labeled standard MOR ligand [ 3 H]-[D-Ala 2 , N-MePhe 4 , Gly-ol]-enkephalin (DAMGO) (4 nM), as demonstrated by the significantly reduced IC 50 at pH 6.5 compared to physiological pH 7.4 ( Fig. 1B,C ). In the [ 35 S]-GTPγS binding assay, the EC 50 of FF3 was significantly lower at pH 6.5 than at pH 7.4 ( Fig. 1E ). In contrast, we found no pH-dependent differences in fentanyl-induced G-protein activation in this assay ( Fig. 1D ). Using real-time fluorescence resonance energy transfer (FRET) in HEK293 cells transfected with MOR, Gβ 1 , Gα i1 -mTqΔ6, and cpVenus-Gγ 2 , we observed dose-dependent dissociation of G-protein subunits (ΔFRET between Gα i1 -mTqΔ6 and cpVenus-Gγ 2 ) upon treatment with fentanyl at both pH 7.4 and 6.5, while FF3 induced dose-dependent effects only at pH 6.5 but not at pH 7.4 (no fitting was found, Fig. 1F ). At pH 6.5 ( Fig. 1G ), time courses of FRET responses to both fentanyl and FF3 (100 μM) differed significantly from those of vehicle-treated cells, whereas at pH 7.4 only fentanyl induced significant effects compared to vehicle ( Fig. 1H ).
FF3 produces analgesia selectively in injured tissue.
To assess analgesic efficacy in vivo, we used four clinically relevant rat models of pain, unilateral complete Freund's adjuvant (CFA)-induced inflammation or plantar incision of the hindpaw, intraperitoneal (i.p.) injection of acetic acid, and unilateral chronic constriction injury (CCI) of the sciatic nerve. Four days following CFA injection ( Fig. 2 ), 2 h after incision (Fig. 3 ), and 14 days following CCI ( Fig. 4 ), rats developed mechanical hyperalgesia indicated by reduced paw pressure thresholds (PPT), mechanical allodynia manifested by decreased paw withdrawal thresholds (PWT) to von Frey filaments, and heat hyperalgesia indicated by lowered paw withdrawal latencies (PWL) in ipsilateral compared to contralateral paws, and to thresholds before injury.
Intravenous FF3 (4-16 μg/kg, i.v.) produced dose-dependent analgesia manifested by increased PPT, PWT, and PWL between 15-45 min after injection. These effects occurred exclusively ipsilateral to the injuries, without affecting contralateral paws. The most effective doses of FF3 (16 and 12 μg/kg, i.v.) reversed PPT, PWT, and PWL in ipsilateral paws to values before CFA injection ( Fig. 2) , incision ( Fig. 3 ), or CCI ( Fig. 4 ). Abdominal constrictions (writhings), evaluated over 30 min after i.p. acetic acid (1%), were dose-dependently attenuated by FF3 (4-16 µg/kg, i.v.) injected 5 min after acetic acid (see Supplementary Fig. S1 ).
To examine the contribution of peripheral opioid receptors, we used naloxone methiodide (NLXM), an opioid receptor antagonist that does not cross the blood-brain barrier 10 , in the CCI model. The analgesic effects produced by FF3 (12 μg/kg, i.v.) in ipsilateral limbs were abolished by NLXM (50 µg) injected at the nerve injury site ( Fig. 4D ), indicating that FF3-induced analgesia is mediated by local opioid receptors. No changes were observed in contralateral paws ( Fig. 4D ).
FF3 induces central and intestinal side effects at high doses.
Next, we examined typical opioid side effects mediated centrally or intestinally (sedation, motor impairment, reward, respiratory depression, constipation). Analogous to our previous study 5 , we tested FF3 (30-150 µg/kg) in comparison to the standard opioids fentanyl (30 µg/kg) and morphine (1-64 mg/kg) following subcutaneous (s.c.) injection.
Locomotor activity, measured as the distance traveled within 30 min after drug injections, was decreased by fentanyl (30 µg/kg), and by the highest doses of morphine (16 mg/kg) and FF3 (150 µg/kg) ( Fig. 5A ). At 5 min after administration of any compound, locomotor activity was significantly lower compared to vehicle (see Supplementary Fig. S2 ). Impaired motor coordination, measured by an accelerating Rota-Rod, was produced by fentanyl (30 µg/kg), by all doses of morphine (2-16 mg/kg), and by the two highest doses of FF3 (60-150 µg/kg) ( Fig. 5B ). Constipation, assessed as reduced defecation, was evoked by fentanyl (30 µg/kg), by all doses of morphine (1-16 mg/kg), and by the highest dose of FF3 (150 µg/kg) ( Fig. 5C ). In the unbiased conditioned place preference test, fentanyl (30 µg/kg), morphine at most doses (2-16 mg/kg), and FF3 at all doses (30-150 µg/kg) produced preference for the drug-associated compartment ( Fig. 5D ). Heart rate ( Fig. 6A ) and oxygen saturation ( Fig. 6B ) were transiently (5-15 min) reduced by FF3 at the highest dose (150 µg/kg), whereas morphine impaired these parameters at all doses (8-64 mg/kg) over the entire period (60 min). Respiratory rate was unaffected by FF3 (30-150 µg/kg), and transiently elevated by morphine (16-32 mg/kg) ( Fig. 6C ).
Discussion
We now expanded our concept to develop pain killers that selectively target opioid receptors in peripheral damaged tissues. We have refined the computational simulations to study injury-specific opioid agonists based on decreased pK a values and altered ligand-receptor interactions. Binding and activation of MOR by the new compound FF3 was enhanced at acidic pH. In models mimicking inflammatory, postoperative, neuropathic, and abdominal pain, FF3 dose-dependently reduced nociception exclusively in the injured tissues. Importantly, injury-induced tissue acidosis was measured in inflammatory and postoperative pain models 5 . However, high doses of FF3 induced sedation, motor impairment, reward, constipation, and respiratory depression.
In contrast to other strategies to achieve analgesia without side effects such as ion channel antagonists, bivalent opioid receptor ligands, biased ligands, abuse deterrent opioids (reviewed in 9 ), the activation of peripheral opioid receptors selectively eliminates the source of pain generation in injured tissues. To this end, we pursued a novel pharmacodynamics-based approach analyzing interactions between opioid receptors and ligands in injury-induced tissue inflammation and acidosis. These studies underlined the importance of protonation for receptor binding and activation. In contrast to commonly used opioid drugs (Table 2) , our previously designed ligand NFEPP with a pK a value reduced to 6.8 displayed enhanced binding and activation of MOR in vitro, and analgesic activity selectively in injured tissue without side effects in vivo 5 .
Additional quantum chemical calculations suggested replacement of hydrogens at an alternative position in the fentanyl molecule, as denoted by the derivatives 12 and 13 in Fig. 1A of our previous publication 5 . Among possible electronegative moieties reducing pK a values (in decreasing order of the relative inductive effect: NH 3
the fluorine atom is the most suitable because one hydrogen is replaced by only one other atom, thus avoiding significant changes in the overall size or geometry of the molecule. According to our original simulations, the racemic molecule FF3 had an estimated mean pK a value of 5.21 and more negative binding energies (Gibbs free energy, ΔG) under injured/acidic conditions (mean ΔG of H-F12 and H-F13 = −13.45) compared to noninjured/neutral conditions (mean ΔG of H-F12 and H-F13 = −9,25) 5 . Here, we refined our pK a estimation by another method 11, 12 . The previous calculations were based on only one three-dimensional structure of each derivative 5 . This is suboptimal, since these molecules are flexible in reality. We now used the structural formula of the molecule as a starting point, and averaged the pK a estimation/calculation for a canonical ensemble of different structures 13 . The recalculated pK a of FF3 (6.01) is now closer to the experimentally obtained value (7.22) . However, there are still differences between calculated (both methods) and experimentally determined pK a values, which are most likely due to the difficulty to determine solvation energies by computational methods 14 .
Although generally recommended 12 , neither of these calculations used experimentally obtained pK a values of related molecules because such measurements were not available so far. Previous publications on computational methods for pK a estimation suggest that approaches based on first principles (as in the present study) are preferable to empirical models based on statistics 15 . Therefore, a combination of our method with experimentally obtained pK a values of related molecules appears most promising for the future.
Some results obtained with FF3 were similar to NFEPP 5 : FF3-induced MOR binding and G-protein dissociation dropped at physiological pH compared to acidic conditions (Table 1) . Mechanical and thermal hyperalgesia as well as mechanical allodynia were reduced exclusively in injured limbs without effects in the contralateral uninjured limbs. Additionally, FF3 produced dose-dependent analgesia in the abdominal writhing assay. NLXM reversed the analgesic effect of FF3 in the CCI model, supporting the selective activation of peripheral opioid receptors. In contrast to NFEPP, FF3 produced side effects at higher dosages than those eliciting analgesia. In particular, our finding that FF3 induced conditioned place preference indicates its abuse liability. It is most likely that a pK a value of 7.22 is not low enough to restrict FF3′s activity to injured/acidic tissue, although analgesic doses did not affect contralateral/healthy limbs in the nociceptive tests. This supports our hypothesis that the pK a of a ligand should be close to the pH of injured tissue (as shown for NFEPP, see Table 1 ) to obtain selective peripheral analgesia without side effects. In addition, possible changes of receptor conformation due to acidosis-induced altered protonation states of amino acid residues must be taken into account in the design of ligands. Thus, further refinement of the computational calculations is necessary to enable reliable pK a predictions leading to novel structures of peripherally selective agonists.
Methods
Quantum chemical pK a calculations. The pK a -values were estimated using Gaussian 09 16 and the quantum-chemical method published previously 13 . To predict Gibbs free energy changes correlated with deprotonation in water, the geometries of fentanyl and FF3, in gas-phase and in solution, were fully optimized employing density functional theory using B3LYP with the 6-31 + G* basis set (Becke's three-parameter hybrid exchange functional and Lee-Yang-Parr correlation functional). In solvation calculations, the integral equation formulation of the polarizable continuum model (IEF-PCM) was applied. Thermal corrections to the Gibbs free energy at 298.15 K were determined at the same level. To consider the dependency of the pK a -value on the molecular conformation 13 , pK a calculations for either molecular species were performed from 10 different starting conformations, generated by 10 ns gas-phase molecular dynamics simulations at 298.15 K using GROMACS 2016.1 17 . Figure 2 . Systemic FF3 dose-dependently reduces pain selectively in inflamed tissue in the CFA model. Effects after intravenous (i.v.) injection of FF3 in rats with unilateral hindpaw inflammation on mechanical (PPT (A) and PWT (B)) and heat (PWL (C)) thresholds in inflamed (left panels) and noninflamed (right panels) hindpaws were measured before (0) and 15-60 min after injection, on day 4 after CFA (*P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle, two-way RM-ANOVA and Bonferroni's multiple comparison test, n = 9, means ± SEM). FF3 was synthesized according to our design by a contractor (ASCA GmbH, Berlin, Germany) leading to the racemate FF3 (Fig. 1B) . The experimental measurement of the pK a value was performed by a contractor (Sirius Analytical Ltd., Forest Row, UK). For in vitro experiments, fentanyl and FF3 were initially dissolved in water or dimethyl-sulfoxide (DMSO) and diluted in assay buffer to final concentrations. For in vivo experiments, FF3 was dissolved in DMSO and diluted with 0.9% NaCl to obtain the final concentrations. The maximum DMSO concentration was 4.2% for s.c., and 0.5% for i.v. injections. Fentanyl and NLXM were dissolved in 0.9% NaCl. Control groups were treated with DMSO or NaCl, respectively.
Cell cultures.
Wild type and MOR-expressing HEK293 cells were maintained in DMEM media (Sigma-Aldrich, Taufkirchen, Germany) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in the absence or presence of 0.1 mg/ml geneticin (Biochrom AG, Berlin, Germany), respectively, in 5% CO 2 at 37 °C. According to their confluence, cells were passaged 1:3-1:10 every second to third day from P8 to P28 18 . Radioligand binding assays. HEK293 cells stably expressing rat MOR were cultured in flasks with a growth area of 175 cm². Cells were washed twice with ice-cold assay buffer (Trizma ® Preset Crystals, 50 mM, pH 7.4) (Sigma-Aldrich), then scratched from the culture flask in 10 ml ice cold assay buffer, homogenized and centrifuged twice at 42,000 g for 20 min at 4 °C as described previously 7, 19, 20 . Protein concentration was determined Transfection for FRET measurements. Culture and transfection of wild type HEK293 cells were performed as previously described 5 . Briefly, cells were grown for 24 h (70-90% confluence) on 24 mm diameter glass coverslips coated with poly-L-lysine before transfection. 0.3-1 μg cDNA per construct were transfected with X-treme GENE HP DNA reagent (Sigma-Aldrich, Taufkirchen, Germany) following the supplier's recommendations. The plasmid containing the cDNA encoding the FLAG-epitope-tagged rat MOR (oprm1, NM_013071.2) in pcDNA ™ 3.1 vector was provided by Prof. C. Zöllner (University Hamburg, Germany). Rat Gα i1 (Gnai1, NM_013145.1) was tagged within the αb-αc loop (between residues 121 and 122) with a truncated enhanced cyan fluorescent monomeric Turquoise (mTqΔ6), to force the fluorophore into a FRET-promoting orientation 23 .
Gα i1 -mTqΔ6 and tetracysteine (TC)-tagged-Gβ 1 (Gnb1, NM_030987.2) were subcloned into pcDNA ™ 3.1 expression vector between BamH1 or EcoRI and XhoI, respectively. A human construct with circular permutated (cp) Venus-Gγ 2 was kindly provided by Dr. M. Adjobo-Hermans (Department of Biochemistry, Radboud Institute for Molecular Life Science, The Netherlands). The rat variant of cpVenus-Gγ 2 (Gng2, NM_001257349.1) and the PTX-resistant Gα i1 -mTqΔ6 were generated by mutagenesis (N24S and C351I, respectively) using QuikChange ™ Mutagenesis kit, and then checked by sequencing (Source Bioscience Sequencing, Berlin, Germany). The functionality of the transfected G-protein subunits was confirmed by preserved cAMP inhibition by fentanyl in the presence of PTX.
Real-time FRET measurements.
At 48 h after transfection of HEK293 cells with MOR, Gβ 1 , Gα i1 -mTqΔ6, and cpVenus-Gγ 2, FRET between the latter two proteins was measured. Cells were briefly washed with PBS and subsequently equilibrated with assay buffer (140 mM NaCl, 5 mM KCl,2 mM CaCl 2 , 2 mM MgCl 2 , 10 mM HEPES, 10 mM Glucose) at different pH values. We used a FRET Nikon Eclipse TE2000-S widefield microscope equipped with a ultra-high-quality monochrome camera DS-Qi1, a Paw incision. Unilateral hindpaw incision was induced under isoflurane anesthesia 25 Abdominal writhing. Animals received an i.p. injection of 10 ml/kg 1% acetic acid and were placed individually into transparent cages for observation of abdominal constrictions ("writhing") 26 . Writhes were recorded 5-35 min thereafter.
Nerve injury. Chronic constriction injury (CCI) of the sciatic nerve was induced under isoflurane anesthesia 27 . At the level of the left mid-thigh, 4 loose 4/0 silk ligatures were placed around the nerve and the wound was closed with silk sutures. Experiments were performed 14 days after CCI.
Injections and experimental protocols. Brief isoflurane anesthesia was applied for i.v. (200 μl), i.p., and injections at the site of the nerve injury (100 μl). Subcutaneous (s.c.) injections were performed without anesthesia. Nociceptive tests were performed in separate groups of animals, before and 5-60 min after injections. NLXM was injected at the site of nerve injury immediately before i.v. injection of agonists. Pain thresholds were measured 15 min after injections. All dosages were determined in pilot experiments. The experimenter was blinded to the doses and drug treatments.
Mechanical hyperalgesia (Randall-Selitto test).
Rats were gently held under paper wadding and incremental pressure was applied via a wedge-shaped, blunt piston onto the dorsal surface of the hindpaws using an automated gauge (Ugo Basile, Comerio, Italy). The PPT necessary to induce paw withdrawal was determined by averaging three consecutive trials separated by 15 s intervals. The cut-off was set at 250 g to avoid tissue damage. The sequence of paws was alternated between animals to preclude order effects.
Mechanical allodynia (von Frey test).
Rats were placed separately in clear Plexiglas cubicles located on a stand with anodized mesh. PWT was measured as described elsewhere 28 Heat hyperalgesia (Hargreaves test). Rats were placed separately in clear Plexiglas cubicles located on a stand with a glass surface. A high-intensity light bulb generated radiant heat was applied to the plantar surface of the hindpaws from underneath the glass surface. PWL was measured using an electronic timer as described 29 . Three measurements separated by at least 10 s were averaged. The heat intensity was adjusted to obtain a baseline withdrawal latency of about 10-12 s in uninjured paws, and the cut-off was 20 s.
Conditioned Place Preference (CPP).
We used an unbiased counterbalanced CPP protocol in healthy rats as described previously 5, 30, 31 . The CPP boxes consist of light-and sound-attenuating chambers (60 × 30 × 30 cm; Ugo Basile) with two compartments separated by a removable door. The two compartments differed in wall color (black or white with black stripes) and floor texture ("grid" or "hole"). For habituation, each rat was placed into the chamber without separator to freely explore it for 30 min (days 1 and 2). In the pre-conditioning phase, each rat was placed into the unseparated chamber for 15 min and the time spent in each compartment was recorded (day 3). Rats showing high unconditioned preference for one of the two compartments were excluded from further analysis, resulting in slightly differing animal numbers (n = 10-12). During conditioning, treatment and treatment-associated compartments were assigned randomly. Each rat underwent three 60 min conditioning sessions receiving the test substance s.c. in one compartment (one session every other day), and three 60 min sessions receiving vehicle in the other compartment on the alternate days (days 4-9). On the test day (day 10), rats did not receive any drug and were allowed to freely explore the entire chamber (without separator) for 15 min. The time spent in each compartment was recorded using the AnyMaze software (Ugo Basile). Place preference was calculated as time spent in the drug-associated compartment subtracted by the time spent in the vehicle compartment.
Locomotor activity. Horizontal locomotor activity of healthy rats was measured in the CPP apparatus on the first day of conditioning of the CPP protocol (day 4). Locomotion was recorded by an infrared camera coupled to a computer with AnyMaze software (Ugo Basile) and was measured as the distance (in cm) traveled in 5 min intervals during 30 min after s.c. drug administration.
Motor coordination (Rota-Rod test).
On the first day naïve rats were trained on the Rota-Rod (Ugo Basile) at 5 rotations per min (rpm). On days two and three the rotating speed was increased to 10 rpm until rats were able to stay on the Rota-Rod for 300 s (maximum 5 trials). On the testing day the data were recorded for three baseline trials prior to drug exposure, followed by three trials at 2, 30 and 60 min after s.c. drug injection at an accelerating speed (10-60 rpm over 300 s). The latency to fall was recorded for 3 successive attempts and averaged for each trial.
Respiratory depression and heart rate. We used a pulse oximeter (MouseOx, StarLife Sciences, Pittsburgh PA, USA) to measure heart rate, respiratory rate, and blood O 2 saturation, as described previously 5 . Briefly, after 2 days of handling and 2 days of habituation (30 min/session), healthy rats were placed in a Plexiglass box wearing the pulse oximeter clip around the neck. The mean of two representative, error-free data sets, were calculated at each time point after s.c. injections.
Defecation. Excreta of individual rats were collected and counted for 1 h after s.c. drug administration on the first conditioning day in the CPP boxes. Data handling and statistical analyses. All data were assessed for normal distribution and equal variances by Kolmogorov-Smirnov test and/or D' Agostino test, and Pearson test. In dose-response experiments (displacement binding and GTPγS-assay), means of values at each agonist concentration and each pH were calculated and used to derive IC 50 and EC 50 by nonlinear regression and were then subjected to unpaired t-test. In FRET experiments, dose-dependent responses were assessed by nonlinear regression setting as a constraint the maximal effect for each drug/pH condition. Normally distributed data were analyzed by one-way repeated measurements (RM)-ANOVA followed by Dunnett's test. Behavioral data were expressed as raw values or area under the curve. Two-sample comparisons were made using paired or unpaired t-test for normally distributed data, or Wilcoxon or Mann-Whitney test for non-normally distributed data. Changes over time (more than two time points) after one treatment were evaluated using one-way RM-ANOVA followed by Bonferroni test for normally distributed data, or Friedman one-way RM-ANOVA followed by Dunn's test for non-normally distributed data. Two-way RM-ANOVA and Bonferroni test were used to compare two parameters over time. Multiple comparisons at one time point were performed using one-way ANOVA followed by Dunnet's test or Bonferroni's multiple comparison test for normally distributed data, or by Kruskal-Wallis one-way ANOVA followed by Dunn's test for non-normally distributed data. Differences were considered significant if P < 0.05. Prism 5 (GraphPad, San Diego, USA) was used for all tests and graphs and all data were expressed as means ± standard error of the mean (SEM).
